Previous studies showed that the levels of IGF1 tend to be reduced in plasma of AD patients [86] and that APP.PS1 mice, crossed with a strain engineered to have reduced circulating IGF1 levels, are characterized by high brain amyloid burden [87]. Here, APP is linked to Alzheimer disease.